Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated liposomal doxorubicin plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer in elderly women
2006-007089-12Phase 2Active
- Sponsor
- GOIM
- Start
- May 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of doxorubicin and trastuzumab in HER2-enriched breast cancer (HER2+), sponsored by GOIM. Primary endpoint: Efficacy and tolerability of the chemotherapeutic combination. Started May 2007; status: active.
02
Drugs
doxorubicintrastuzumab
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on 2006-007089-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-007089-12.